NOW AVAILABLE: For the International Biosimilars Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.
Benepali/Brenzys produced most of the promotional materials (46%) during this quarter. Overall, biosimilars highlighted comparability and safety when switching from biologics to biosimilars in Europe, while Canada promoted Brenzys as the first subcutaneous anti-TNF biosimilar approved in Canada that provides a low-cost therapy. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.
Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.
Reports are available by annual subscription for over 50 primary and specialty markets.
For more information please contact:
US Markets: Christine Alongi at Alongi@dtwresearch.com
Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com